Epstein-Barr virus-associated post transplant lymphoproliferative disease (PTLD) is a typical and commonly fatal complication after allogeneic stem cell transplantation (SCT) 1 with an incidence between 1 and 2%, independent of stem cell source. [2] [3] [4] [5] The occurrence is highest in the first months after transplantation (ie early onset defined as PTLD o6 or 12 months after SCT) and only few cases present more than 1 year after SCT. 4, 5 Here, we report about the, to our knowledge, first report of lateonset EBV-associated PTLD in a patient with Omenn's syndrome or SCID after umbilical cord blood transplantation.
An 18-month-old boy received unrelated umbilical cord blood transplantation with no HLA mismatch because of Omenn's syndrome, as reported previously. 6 The umbilical cord blood was seronegative for EBV, and EBV PCR was negative as well. Conditioning The child achieved neutrophil engraftment on day þ 34 (defined as the first day of neutrophils 4500/ml over 3 consecutive days) and platelet engraftment on day þ 48 (450 000/ml for the first of 7 consecutive days without the need for transfusion). However, although reconstitution of CD56 þ NK cells and CD19 þ B cells occurred rapidly, the number of T cells and CD4 and CD8 T cells increased only very slowly and was still far below the normal range for this group of age 24 months after SCT (Figure 1a) . Moreover, analysis of sorted B-, T-and PMN cells 10 weeks after SCT showed incomplete chimerism with only 6, 12 and 11% respectively of donor DNA. The percentage of donor DNA thereafter increased gradually but still persisted (Figure 1b) . The child showed no signs of acute GvHD. Immunosuppressive treatment with cyclosporin A and methylprednisolone was discontinued on days þ 61 and þ 74, respectively. Follow-up for 2 years after SCT was uneventful with no major infections, or signs of chronic GvHD. Prophylaxis with intravenous immunoglobulins was maintained throughout the entire period. However, 26 months after SCT, a de novo EBV infection with fever up to 401C, lymphadenopathy, hepatosplenomegaly and respiratory symptoms was diagnosed. Chest X-ray and CT scan were performed demonstrating pulmonary infiltrates and signs of fibrosis. Histopathological analysis of lung and lymph node biopsy revealed a diffuse large B-cell lymphoma in association with EBV infection. At this time, CD3 þ and CD4 þ T cells dramatically dropped down and also the number of B cells decreased finally. High amounts of EBV DNA could be detected with 32 000 genome copies/ml in plasma and 320 000 copies in 10 5 PBMC at the beginning, increasing up to 250 000 copies/ml in plasma as well as 600 000 copies in 10 5 PBMC, respectively. The child was treated with ganciclovir (10 mg/kg body weight), which was changed to acyclovir (45 mg/kg body weight) after 2 weeks because of ineffectiveness. He received systemic corticosteroids for 21 days, which slightly improved respiratory function. For treatment of PTLD, rituximab 20 mg/kg i.v. was administered twice without leading to a decrease in EBV load.
Despite treatment, pulmonary disease finally worsened requiring ventilation. The child died of systemic multiorgan failure 29 months after SCT. Autopsy revealed involvement of intestine and tonsils of PTLD in addition to lung and lymph nodes.
Risk factors of EBV-associated PTLD include T-cell depletion, HLA mismatch, donor age above 18 years, occurrence of acute GvHD grades II-IV, conditioning regimens containing irradiation, use of antithymocyte globulin or anti-CD3 monoclonal antibody. Especially for late-onset PTLD, primary immunodeficiency has been found to be a major risk factor with an incidence of over 8% (Barker et al, 2001 ). 5 However, these patients often receive T-cell-depleted grafts from a haploidentical parent (7/8 patients in the study by Gross et al), combining T-cell depletion and mismatching as significant risk factors for PTLD. The importance of these risk factors is shown in an analysis by Filipovich: 7 the incidence of PTLD in SCT for immunodeficiency was 32% for T-cell-depleted haploidentical SCT, 8% for unrelated donor transplants and 0% using a graft from a matched sibling donor.
In the patient reported here, the extreme delay in T-cell recovery and the mixed chimerism could also be a possible cause for PTLD, since it is generally well recognized that EBV-associated PTLD develops on the basis of T-cell lymphopenia or dysfunction. This case report shows that the risk of developing an EBV-associated PTLD continues to persist late after unrelated umbilical cord blood in patients with SCID and therefore these patients should be monitored for EBV-PTLD longer than previously assumed. Future studies are warranted to investigate the usefulness of prophylactic antiviral treatment in these patients. 
